Medical sector’s Adverum Biotechnologies’s (NASDAQ:ADVM) Hold rating Reiterated by SVB Leerink LLC – 4 stars

Adverum Biotechnologies (NASDAQ:ADVM)‘s stock had its Hold rating Reiterated by analysts at SVB Leerink LLC – 4 stars in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 201.2M and a beta of 1.2.  Adverum Biotechnologies has a twelve month low $2.00 of  and a twelve month high of $14.79.

Shares of Adverum Biotechnologies traded down -$0.01 on monday, reaching $2.05. 1,120,929 shares of the stock traded hands, compared to its average volume of 2964955. Shares of Adverum Biotechnologies at close on monday were at $2.05. The firm’s 50 day moving average is $$2.30 and its 200 day moving average is $6.54.Adverum Biotechnologies  has a 12 month low of $2.05 and a 12 month high of $14.79. While on yearly highs and lows, Adverum Biotechnologies’s today has traded high as $2.13 and has touched $2.05 on the downward trend. See More Analyst Rating at: RATING

Adverum Biotechnologies (NASDAQ:ADVM) Moving Average Technical Analysis

5 day Moving Average is $2.08 And 5 day price change is -$0.35 (-14.58%)  with average volume for 5 day average is 3,348,220. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $2.21 and 20 day price change is -$0.22 (-9.69%) and average 20 day moving volume is 3,818,120. 50 day moving average is $2.30  and 50 day price change is -$0.22 ( -9.69%)  and with average volume for 50 days is : 2,328,684. 200 day moving average is $6.54  and 200 day price change is -$10.44 (-83.59%)  and with average volume for 200 days is : 2,061,792.

See More Analyst Rating at: RATING

Adverum Biotechnologies Earnings and What to expect: 

Adverum Biotechnologies last issued its earnings data on August 4th, 2021. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.07. Adverum Biotechnologies has generated ($1.38) earnings per share over the last year (($1.44) diluted earnings per share). Earnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.54) to ($1.47) per share. Adverum Biotechnologies has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Adverum Biotechnologies are expected to grow in the coming year, from ($1.54) to ($1.47) per share. The P/E ratio of Adverum Biotechnologies is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Adverum Biotechnologies is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Adverum Biotechnologies has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Other owners latest trading in Adverum Biotechnologies :

  • On 9/17/2021 shares held by Virtu Financial LLC were 73,955 which equates to market value of $0.26M and appx 0.00% owners of Adverum Biotechnologies
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 143,051 which equates to market value of $0.50M and appx 0.00% owners of Adverum Biotechnologies
  • On 8/23/2021 shares held by Morgan Stanley were 958,190 which equates to market value of $3.35M and appx 0.00% owners of Adverum Biotechnologies
  • In total Institutional ownership equates to Institutional Ownership Percentage: 80.69% for Adverum Biotechnologies

See More Analyst Rating at: RATING